Ashfield, part of UDG Healthcare plc, today announced the formation of three business units to bolster its integrated healthcare services across strategic consulting, benchmarking, commercialisation, customer engagement, events, marketing and communications.
The creation of the three business units; Ashfield Advisory, Ashfield Engage and Ashfield Health, follows Ashfield’s strategic acquisition of 22 businesses over the last 10 years aimed at strengthening its integrated service portfolio to support its clients, healthcare professionals and their patients.
The move is also in direct response to continued demand from clients for deeper partnerships and will enable greater collaboration between Ashfield’s experts to solve multi-faceted and complex challenges.
The three business units clearly articulate the capabilities within each business unit and how each can support Ashfield’s diverse range of healthcare and life science companies:
“Ashfield has always been driven by a desire to redefine and develop richer client partnerships, improving customer experience and outcomes. Our business has evolved in recent years due to a number of strategic and complementary acquisitions, and our new structure tells a simpler, stronger story. Most importantly, it enables our clients to access a breadth of industry-leading solutions and experience our collective expertise, combined with outstanding execution.” explains Ryan Quigley, Chief Operating Officer of Ashfield and UDG Healthcare plc.
“Throughout Ashfield, we are connected by imagination, strategy and action, in everything we do. Our capabilities in data and digital engagement are a good example of this and through innovative approaches we are enabling our clients to adapt to the present pandemic as well as helping them to prepare for the future. Our integrated offering will allow us to better meet clients’ needs, tackle their challenges with ingenuity and create tangible solutions.”
ADVANZ PHARMA partners with Ashfield Engage to deliver talent acquisition strategy for European specialty medicine division.
Read moreAshfield Engage has announced a strategic partnership with respiratory drug developer Synairgen plc (LSE: SNG).
Read more